Journal of Asthma and Allergy最新文献

{"title":"Acupuncture for Persistent Asthma: Protocol for a Randomized, Sham-Controlled Trial with Neuroimaging.","authors":"Yangke Mao, Pan Zhang, Zilei Tian, Ling Huang, Siyi Yu, Zhaoxuan He, Zaiyi Luo, Ziyi Chen, Ruyi Zhao, Xiaohui Dong, Jing Gao, Fang Zeng","doi":"10.2147/JAA.S615234","DOIUrl":"10.2147/JAA.S615234","url":null,"abstract":"<p><strong>Background: </strong>Although acupuncture has shown therapeutic potential for asthma, its clinical application is limited by insufficient high-quality evidence and an incomplete understanding of its neurophysiological mechanisms. This study aims to evaluate the efficacy and safety of acupuncture in patients with persistent asthma and to further investigate its central mechanisms.</p><p><strong>Methods: </strong>This randomized, sham-controlled neuroimaging trial will enroll 72 patients with mild-to-moderate persistent asthma. Participants will be randomly assigned in a 1:1 ratio to receive either genuine or sham acupuncture. The intervention comprises 12 sessions over 4 weeks. The primary outcome is the change in the Asthma Control Test score from baseline to week 4. Secondary outcomes encompass scores from the Asthma Quality of Life Questionnaire, Self-Rating Anxiety Scale, Self-Rating Depression Scale, Pittsburgh Sleep Quality Index, Montreal Cognitive Assessment, along with forced expiratory volume in 1 second and fractional exhaled nitric oxide levels. Cerebral changes will be assessed via magnetic resonance imaging conducted before and after the treatment course. Statistical analyses will adhere to the intention-to-treat principle and will employ analysis of covariance and linear mixed-effects models. Furthermore, correlation and mediation analyses will be performed to investigate the relationships between clinical improvements and neuroimaging data, thereby exploring potential neurobiological mechanisms of acupuncture.</p><p><strong>Discussion: </strong>This randomized controlled trial aims to evaluate the clinical efficacy and central neural mechanisms of acupuncture in patients with persistent asthma. The findings are expected to provide evidence supporting its therapeutic role. By elucidating the underlying neuroregulatory mechanisms, this study may contribute to a more mechanism-informed and optimized application of acupuncture in asthma management.</p><p><strong>Trial registration: </strong>This trial is registered on the International Traditional Medicine Clinical Trial Registry (http://itmctr.ccebtcm.org.cn/) on April 2025 (ITMCTR2025000737).</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"19 ","pages":"615234"},"PeriodicalIF":3.3,"publicationDate":"2026-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13243360/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148211358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of the P2X₃ Antagonist Gefapixant for Refractory Atopic Cough: A Retrospective Cohort Study.","authors":"Yoshihisa Ishiura, Shosaku Nomura, Noriyuki Ohkura, Johsuke Hara, Masaki Fujimura, Tomoki Ito","doi":"10.2147/JAA.S603501","DOIUrl":"10.2147/JAA.S603501","url":null,"abstract":"<p><strong>Background: </strong>Atopic cough, arising from hyperresponsiveness of afferent airway C-fibers, is common, and cough is one of the commonest reasons for referral to respiratory clinic. Gefapixant is a first-in-class P2X₃ receptor antagonist recently approved for use in patients with refractory cough to inhibit airway C-fiber activation. We conducted this study to investigate the clinical effect of gefapixant in patients with refractory atopic cough that responded only partially to azelastine monotherapy.</p><p><strong>Methods: </strong>This was a single-center retrospective observational study. Patients with refractory atopic cough received gefapixant. Collected retrospectively from medical records, data included cough symptom questionnaire responses and results from respiratory function tests, cough reflex sensitivity tests, and blood tests.</p><p><strong>Results: </strong>Data from 23 patients with refractory atopic cough were included in this study. Spirometry parameters, fractional exhaled nitric oxide levels, peripheral eosinophil counts, and IgE levels were unchanged after gefapixant treatment. Scores for the cough severity visual analog scale and Leicester cough questionnaire significantly improved after treatment with gefapixant (both p<0.01). Cough reflex sensitivity to inhaled capsaicin also significantly improved after treatment with gefapixant (p<0.01).</p><p><strong>Conclusion: </strong>The P2X₃ antagonist gefapixant appeared to improve patient-reported symptoms and cough reflex hypersensitivity in a retrospective cohort of patients with refractory atopic cough. These findings suggest P2X₃ antagonists may be a treatment option for refractory atopic cough, possibly through possibly through reducing hypersensitivity of airway C fibers.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"19 ","pages":"603501"},"PeriodicalIF":3.3,"publicationDate":"2026-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13242768/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148205139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiorespiratory and Glycaemic Changes Following Prehospital Nebulised Salbutamol in Acute Asthma: A Mixed Retrospective and Prospective Observational Study.","authors":"Craig Mortimer, Dimitra Nikoletou, Ann Ooms, Julia Williams","doi":"10.2147/JAA.S605135","DOIUrl":"10.2147/JAA.S605135","url":null,"abstract":"<p><strong>Purpose: </strong>In 2010, the Global Strategy for Asthma Management and Prevention recommended reducing the reliance on treating acute asthma exacerbations with short-acting β₂ agonists (SABAs) given potential adverse effects. However, more than a decade later, SABAs, particularly nebulised salbutamol, remain at the forefront of acute asthma care. This study examined the physiological effects of nebulised salbutamol in patients experiencing moderate to severe asthma exacerbations.</p><p><strong>Methods: </strong>A six month, prospective and retrospective observational study was undertaken involving prehospital asthma patients treated with nebulised salbutamol. Data were analysed using descriptive and inferential statistics, including paired comparisons and exploratory subgroup analyses, to identify relevant trends and variability.</p><p><strong>Results: </strong>Among 176 eligible patients, reductions were observed in heart rate (mean -3 beats/min) and respiratory rate (mean -5 breaths/min), with modest improvement in peripheral oxygen saturation (+2%). Capillary blood glucose (CBG) analysis was conducted on a small prospective subgroup (n=8). A mean increase of +0.375 mmol/L was observed. When one clinically atypical outlier was excluded (n=7), the increase reached statistical significance. Albeit interpretation is limited by the small sample size.</p><p><strong>Conclusion: </strong>Administration of ≥5mg nebulised salbutamol in acute asthma exacerbations was transiently associated with improved peripheral oxygen saturation and respiratory parameter changes during the prehospital treatment period. No clinically significant increase in heart rate was observed overall. A small rise in CBG was observed in a small prospectively monitored subgroup. However, the clinical significance of this finding remains uncertain. Larger, adequately powered prospective studies are required to confirm these findings. The present findings are insufficient to recommend changes to current glucose monitoring practices in non-diabetic patients.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"19 ","pages":"605135"},"PeriodicalIF":3.3,"publicationDate":"2026-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13242825/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148205054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Appropriate Use of Single Inhaled Triple Therapy in Uncontrolled Asthma: A Multinational Modified Delphi Consensus.","authors":"Dilsad Mungan, Arturo Cortes-Telles, Mahmoud Mokhtar, Federico Daniel Colodenco, Martin Maillo, P K Thomas, Sanjeev Mehta, Mohamed S Al-Moamary, Hind Tahoon, Razia Hussain, James Van Hasselt, Nicola A Hanania","doi":"10.2147/JAA.S590236","DOIUrl":"10.2147/JAA.S590236","url":null,"abstract":"<p><strong>Introduction: </strong>Uncontrolled asthma is associated with impaired lung function, higher frequency of severe exacerbations, reduced quality of life, and increased healthcare costs. Although inhaled corticosteroids with long-acting β2-agonists (ICS/LABA) form the cornerstone of treatment, many patients continue to experience suboptimal disease control. Despite additional therapeutic strategies, their utilization is inconsistent. We conducted a modified Delphi consensus among expert clinicians to understand their perceptions of treatment strategies in uncontrolled asthma and evaluate their approaches beyond ICS/LABA therapy with a focus on single-inhaler triple therapy and other add-on options, including biologics.</p><p><strong>Methods: </strong>The study consisted of two rounds of online surveys and a panel meeting involving 27 respiratory experts from nine countries. A 59-statement questionnaire (52 consensus statements, seven open) was developed following a literature review. Responses were recorded using a 9-point scale ranging from 1 (disagreement) to 9 (agreement) with a consensus threshold of 75%.</p><p><strong>Results: </strong>All experts participated in both surveys, and 22/27 attended a virtual panelists' meeting. Consensus was reached on 39/52 and 3/13 statements in surveys-1 and -2, respectively. Most panelists (15/27) estimated that 26-50% of their patients with asthma have uncontrolled disease. Improvement in symptoms and reduction in exacerbations were perceived as key indicators of asthma control (96% agreement). Additionally, 93% agreed that adding a long-acting muscarinic antagonist (LAMA) to medium-high dose ICS/LABA is a valid option for patients with uncontrolled asthma, citing benefits in symptom relief, lung function, and exacerbation reduction. Consensus was not reached on the use of azithromycin, leukotriene modifiers or biologics in this population.</p><p><strong>Conclusion: </strong>In this modified Delphi consensus, international respiratory experts agreed on adding LAMA in patients who remain uncontrolled on medium-high dose ICS/LABA. Most consensus statements aligned with prevalent guidelines. However, divergent opinions on the use of azithromycin, leukotriene modifiers or biologics highlight the need for evidence-informed treatment decisions.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"19 ","pages":"590236"},"PeriodicalIF":3.3,"publicationDate":"2026-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13221441/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148138217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Comparative Study of Type 2 Inflammatory Biomarkers Combined with Small Airway Parameters for Diagnosing Cough-Variant Asthma.","authors":"Eloina Margarita Mokuy Ondo Osie, Haodong Bai, Jianjun Liu, Zihang Wang, Tongyangzi Zhang, Siwan Wen, Li Yu, Xianghuai Xu","doi":"10.2147/JAA.S609152","DOIUrl":"10.2147/JAA.S609152","url":null,"abstract":"<p><strong>Background: </strong>The diagnosis of cough-variant asthma (CVA) traditionally relies on clinical manifestations and bronchial provocation test (BPT). However, the BPT can be costly and complex, and poses risks of severe bronchospasm. Most CVA patients exhibit type 2 airway inflammation and small airway dysfunction. Identifying practical biomarkers such as total immunoglobulin E (tIgE), percentage of eosinophil cell count in induced sputum (sEOS%), peripheral blood eosinophil count (PBEC), and fractional exhaled nitric oxide (FeNO) may enhance the diagnostic process for cough-variant asthma.</p><p><strong>Objective: </strong>This study aims to evaluate and compare the diagnostic utility of T2 inflammatory biomarkers combined with small airway parameters for diagnosing CVA.</p><p><strong>Methods: </strong>This was a single-center, cross-sectional diagnostic study including 211 patients with chronic cough. Participants underwent spirometry, FeNO measurement, and assessment of eosinophilic inflammation, including sEOS%, PBEC, and tIgE. Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic performance of individual parameters and combined models.</p><p><strong>Results: </strong>CVA was diagnosed in 27.5% of patients. Compared with non-CVA patients, those with CVA showed significantly higher levels of T2 inflammatory biomarkers and reduced small airway function. Among individual biomarkers, FeNO demonstrated the highest diagnostic accuracy (AUC = 0.79), followed by sEOS% (AUC = 0.75), tIgE (AUC = 0.71), and PBEC (AUC = 0.66). Among small airway parameters, FEF_50% showed the best performance (AUC = 0.79). Combined models significantly improved diagnostic accuracy, with FEF_50% combined with FeNO or sEOS%, achieving the highest AUC (0.82). Correlation analysis revealed that higher inflammatory biomarker levels were associated with reduced small airway function.</p><p><strong>Conclusion: </strong>The combination of T2 inflammatory biomarkers and small airway function parameters improves the diagnostic accuracy for CVA. This approach may provide a practical and non-invasive strategy for identifying CVA, particularly in settings where bronchial provocation testing is not readily available.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"19 ","pages":"609152"},"PeriodicalIF":3.3,"publicationDate":"2026-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13220828/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148138191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Multi-Compartment Cytological Approach to Severe Asthma Phenotyping: The BRISA Study (Biomedical Research in Severe Asthma).","authors":"Javier Domínguez-Ortega, Gabriela Leon-Zambrana, José Antonio Cañas, Ismael García-Moguel, Juan Manuel Igea, Marcela Valverde-Monge, María Luisa Caballero, Mar Gandolfo-Cano, Leticia De Las Vecillas, Santiago Quirce, Victoria Del Pozo","doi":"10.2147/JAA.S591415","DOIUrl":"10.2147/JAA.S591415","url":null,"abstract":"<p><strong>Background: </strong>Accurate inflammatory phenotyping in asthma remains challenging. Nasal cytology has emerged as a potential non-invasive tool to assess airway inflammation in asthma. However, its relationship with lower airway inflammation and systemic biomarkers remains unclear, particularly in severe asthma (SA).</p><p><strong>Objective: </strong>To evaluate whether a multi-compartment approach could improve the characterisation of type 2 inflammation and the relationship between nasal cytology, induced sputum, and systemic inflammatory biomarkers in patients with severe asthma.</p><p><strong>Methods: </strong>In this cross-sectional exploratory BRISA study, twenty-two patients with SA underwent nasal cytology by mucosal scraping, induced sputum analysis, and serum biomarker assessment (periostin, eosinophil cationic protein, thymic stromal lymphopoietin, dipeptidyl peptidase-4, and total IgE). Patients were stratified according to blood eosinophil count (BEC <300 vs ≥300 cells/µL). Correlations between compartments and associations with clinical and inflammatory variables were analysed.</p><p><strong>Results: </strong>Higher blood eosinophil counts were associated with worse lung function, increased exacerbations, and higher serum periostin levels. Valid induced sputum samples were obtained in 16 patients: 7 eosinophilic, 3 neutrophilic, 2 mixed eosinophilic-neutrophilic and 4 paucigranulocytic. Nasal cytology predominantly showed limited agreement with induced sputum inflammatory phenotypes. Serum TSLP, DPP4, and IgE also showed an upward trend in patients with higher blood eosinophil counts, although these differences were not statistically significant. Correlation analysis demonstrated a significant positive association between sputum and blood eosinophils, as well as between blood eosinophils and serum periostin. A strong positive correlation was also observed between serum eotaxin and TSLP.</p><p><strong>Conclusion: </strong>Nasal cytology alone cannot replace induced sputum for inflammatory phenotyping in SA, although it may provide complementary information on upper airway inflammation. Among the evaluated systemic biomarkers, periostin emerged as the most consistent marker associated with blood eosinophilia, while other biomarkers showed only non-significant trends. Further studies are needed to validate the role of combined biomarkers in predicting airway inflammation.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"19 ","pages":"591415"},"PeriodicalIF":3.3,"publicationDate":"2026-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13220835/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148138232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multidisciplinary Recommendations for the Use of Chest CT and Bronchial Biopsy in Severe Asthma: An Expert Consensus Based on Real-World Experience.","authors":"Juan Luis Garcia-Rivero, Elena Peña, Ana González-Piñeiro, Mar Mosteiro Añón, Borja G Cosio","doi":"10.2147/JAA.S604260","DOIUrl":"10.2147/JAA.S604260","url":null,"abstract":"<p><strong>Background: </strong>Chest computed tomography (CT) and bronchial biopsy can refine severe asthma phenotyping beyond systemic biomarkers, yet real-world implementation re mains heterogeneous and reporting is often non-standardized. Multidisciplinary integration is therefore needed to maximize clinical utility and comparability across centres.</p><p><strong>Methods: </strong>This manuscript reports a multidisciplinary expert consensus developed during the AGHORA workshop held in Santander, Spain (21-22 November 2025). Experts in severe asthma care, bronchoscopy, thoracic imaging, and pulmonary pathology from 13 predominantly tertiary hospitals participated. Recommendations were generated through structured plenary and discipline-focused sessions followed by cross-disciplinary discussion. Draft statements were refined in real time and submitted to show-of-hands voting; agreement was categorized qualitatively as high, moderate, or low.</p><p><strong>Results: </strong>The panel identified key decision points where CT is most likely to change management, particularly prior to biologic initiation and in cases of inadequate response to biologic therapy. When tracheobronchomalacia/central airway collapse was clinically suspected, expiratory imaging was considered essential. A minimum dataset for CT acquisition and structured reporting was proposed, emphasizing systematic assessment (and, where feasible, quantification) of mucus plugging, bronchial wall thickening/bronchiectasis distribution and extent, and air trapping/small-airway disease patterns, complemented by an actionable impression for multidisciplinary decision-making. For bronchial biopsy, experts agreed on scenarios where tissue assessment adds value (eg, suspected T2 low asthma, discordant biomarkers, and biologic non-response) and proposed minimum technical and reporting standards. Standardized histopathology reporting was anchored to the validated 11-item pathological score (PS score), enabling structured item-level reporting and benchmarking across inflammatory and remodelling domains.</p><p><strong>Conclusion: </strong>This expert statement provides pragmatic, multidisciplinary recommendations and minimum reporting standards for CT and bronchial biopsy in severe asthma. Implementation may reduce inter-centre variability, improve personalized clinical decision-making, and facilitate multicentre research and prospective validation.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"19 ","pages":"604260"},"PeriodicalIF":3.3,"publicationDate":"2026-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13218207/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148138360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision Prediction of Pediatric Subcutaneous Immunotherapy Outcomes Using a Clinical Nomogram for House Dust Mite Allergy.","authors":"Shi-Jie Zhuang, Ting-Ting Fan, Rong-Li Lai, Xin-Yu Ruan, Shi-Min Huang, Zi-Hong Gao, Chun-Yan Liu, Zhi-Wei Lu, Miao-Feng Huang, Xiao-Lan Liu, Fang-Hua Yang, Kun-Ling Shen, Yan Zhang, Yan-Min Bao","doi":"10.2147/JAA.S605382","DOIUrl":"10.2147/JAA.S605382","url":null,"abstract":"<p><strong>Background: </strong>The identification of predictive biomarkers for subcutaneous immunotherapy (SCIT) is of great importance for improving its clinical efficacy. This study aims to construct a nomogram predicting the efficacy of SCIT and to evaluate the predictive value of Der p 1 and Der p 2 for SCIT response.</p><p><strong>Methods: </strong>This study included children with allergic rhinitis (AR) and/or asthma (AS) who received house dust mite (HDM) SCIT at Shenzhen Children's Hospital between 2021 and 2024. Baseline characteristics and laboratory data were retrospectively collected before SCIT. The sIgE to HDM components were measured in children's serum before SCIT. The efficacy of SCIT was assessed with VAS scores. Potential predictors for the efficacy of HDM SCIT were identified with logistic regression analysis. A nomogram predicting the efficacy of HDM SCIT was constructed and internally validated.</p><p><strong>Results: </strong>Among the 209 children who were successfully followed up after one year of treatment, 166 (79%) responded to HDM SCIT, while 43 (21%) were non-responders. Logistic regression analysis identified that Der p (1+2) sIgE, the Der p (1+2) sIgE/tIgE ratio and asthma as predictors of HDM SCIT efficacy. A nomogram predicting the efficacy of HDM SCIT was developed by incorporating the three predictors. The nomogram achieved an AUC of 0.80 (95% CI=0.72-0.87) and a C-index of 0.80 (95% CI=0.72-0.87). At a cutoff value of 43.87kU_A/L, Der p (1+2) sIgE achieved an AUC of 0.75, superior to tIgE and the Der p (1+2) sIgE/tIgE ratio.</p><p><strong>Conclusion: </strong>The Der p 1 and Der p 2 were predictors of HDM SCIT. Der p (1+2) sIgE outperformed both the Der p (1+2) sIgE/tIgE ratio and tIgE in predicting the efficacy of HDM SCIT. A nomogram incorporating Der p (1+2) sIgE, the Der p (1+2) sIgE/tIgE ratio and asthma was developed for the visual and quantitative prediction of HDM SCIT efficacy.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"19 ","pages":"605382"},"PeriodicalIF":3.3,"publicationDate":"2026-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13212172/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148054696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eosinophilic Depletion with Benralizumab, Mepolizumab, and Depemokimab: A Modeling Study.","authors":"Pradeep B Lukka, Robert C Penland, Ari Brekkan, Rami Ayoun Alsoud, Sherri So, David W Boulton","doi":"10.2147/JAA.S605634","DOIUrl":"10.2147/JAA.S605634","url":null,"abstract":"<p><strong>Purpose: </strong>Anti-interleukin (IL)-5/IL-5 receptor therapies are an integral part of the management of patients with severe eosinophilic asthma. We modeled and compared the blood eosinophil (bEOS) depletion response following indicated dosing regimens with benralizumab, mepolizumab, and depemokimab.</p><p><strong>Methods: </strong>Pharmacokinetic (PK)/pharmacodynamic (PD) models were developed to describe antibody concentration and bEOS count in adults. Two PK/PD models were developed using digitized bEOS data reported for depemokimab and mepolizumab, respectively, and one PK/PD model was based on individual PK parameters and predicted bEOS data with benralizumab. Subjects were assumed to receive either benralizumab 30 mg every 4 weeks (Q4W) for the first three doses, then every 8 weeks, mepolizumab 100 mg Q4W, or depemokimab 100 mg every 6 months.</p><p><strong>Results: </strong>At 12 weeks, the predicted median bEOS depletion from baseline was 99.5% (90% prediction interval [PI]: 98.3-99.8) for benralizumab, 76.1% (90% PI: 47.6-89.0) for mepolizumab, and 82.0% (90% PI: 65.0-91.6) for depemokimab. Similar median bEOS depletion rates were predicted at 24 weeks: 99.3% (90% PI: 97.2-99.8) for benralizumab, 76.3% (90% PI: 48.3-89.3) for mepolizumab, and 80.7% (90% PI: 63.2-90.2) for depemokimab. The greater reduction in bEOS count achieved with benralizumab, compared with mepolizumab and depemokimab, was predicted to be sustained through 48 weeks of continued treatment.</p><p><strong>Conclusion: </strong>These PK/PD model simulations predict that benralizumab results in consistently higher bEOS depletion than mepolizumab or depemokimab at 12 and 24 weeks. These results are dependent on the quality of the models and digitized data utilized; other models and parameter estimates may produce different results.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"19 ","pages":"605634"},"PeriodicalIF":3.3,"publicationDate":"2026-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13199611/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148030611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dupilumab is Effective in Young Children with Atopic Dermatitis Regardless of Type 2 Comorbidities.","authors":"Mark Boguniewicz, Lawrence D Sher, Amy S Paller, Peter D Arkwright, Shigemi Yoshihara, Wendy Smith Begolka, Zhen Chen, Parul Shah, Ainara Rodríguez Marco","doi":"10.2147/JAA.S590176","DOIUrl":"10.2147/JAA.S590176","url":null,"abstract":"<p><strong>What is this summary about?: </strong>This is a summary of a post hoc study of the LIBERTY AD PRESCHOOL trial published in October 2024. The trial included 162 infants and children aged 6 months to 5 years who had moderate-to-severe atopic dermatitis (AD). Researchers showed that an injectable drug called dupilumab resulted in improved AD, whether or not patients also had asthma, allergic rhinitis (nasal allergy), or food allergy, diseases that are closely related to AD.</p><p><strong>What are the key takeaways?: </strong>We found that dupilumab improved AD in the infants and children, whether or not they also had one of the other related diseases.</p><p><strong>What were the main conclusions reported by the researchers?: </strong>Dupilumab works well to treat infants and children with AD, even if they also have asthma, allergic rhinitis, or food allergy. Dupilumab was well tolerated and overall safety was consistent with the known dupilumab safety profile.</p><p><strong>Clinical trial number: </strong>: NCT03346434.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"19 ","pages":"590176"},"PeriodicalIF":3.3,"publicationDate":"2026-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13244477/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148211394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}